Business context and reporting period
The filing is a Form 10-Q for the quarter ended March 31, 2019. Although the request metadata names Alaunos Therapeutics, the filing itself identifies the registrant as ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). Ziopharm was a development-stage biopharmaceutical company focused on immuno-oncology, including its Sleeping Beauty cell-therapy and Controlled IL-12 platforms. It reported no recurring operating revenue.
Key financial metrics
Amounts below are in U.S. dollars; financial statement figures are in thousands unless otherwise noted.
| Metric | Q1 2019 | Q1 2018 or comparison |
|---|---|---|
| Collaboration revenue | $0 | $146 |
| Research and development expense | $9.476 million | $10.183 million |
| General and administrative expense | $4.145 million | $6.159 million |
| Net loss | $13.434 million | $16.020 million |
| Basic and diluted net loss per share | $0.08 loss | $0.15 loss |
| Cash used in operating activities | $10.232 million | $18.957 million |
| Cash and cash equivalents at period end | $51.487 million | $61.729 million at Dec. 31, 2018 |
At March 31, 2019, current assets were $74.093 million, current liabilities $8.339 million, and working capital approximately $65.8 million. Total liabilities were $9.287 million, primarily current operating costs and lease liabilities; the filing reports no conventional borrowings. Accumulated deficit was $579.763 million. The company had 162.287 million common shares outstanding at quarter-end and 162.394 million as of April 30.
Changes versus the prior comparable period
- Revenue fell to zero from $146,000 because the company had no remaining contract liability under its Ares Trading collaboration to recognize as revenue.
- R&D expense declined 7% year over year. A $2.3 million reduction in clinical and development costs associated with the transfer of CD33-specific CAR-T activities to Precigen was partly offset by increased gene-therapy trial and personnel costs.
- G&A expense declined 33%, mainly because Q1 2018 included approximately $2.2 million of stock-option modification expense related to a departing officer and director.
- Net loss narrowed by about $2.6 million. Operating cash use also decreased, although quarter-end cash fell $10.242 million from year-end 2018.
- Adoption of the lease accounting standard in January 2019 added approximately $1.6 million of right-of-use assets and $1.6 million of lease liabilities, with no material effect on earnings or accumulated deficit.
Outlook, management commentary, risks and contingencies
- Management estimated that existing cash would fund planned operations into the second quarter of 2020. The company had no committed additional capital and said further financing would be needed for its longer-term plans; inability to raise funds or secure partnerships could force delays, reductions, or discontinuation of programs.
- Near-term development plans included an NCI Phase 1 trial of Sleeping Beauty-modified TCRs expected to begin in mid-2019; a U.S. Phase 1 trial of rapid-manufacture CD19 CAR-T, subject to responding to FDA information requests; and continued Controlled IL-12 studies, including a planned Phase 2 recurrent glioblastoma trial with Libtayo. FDA Fast Track designation for Controlled IL-12 was announced April 1, 2019, after quarter-end.
- In February 2019, the company extended its NCI CRADA by two years, committing an additional $5.0 million. The remaining CRADA obligation was $6.875 million. Total disclosed contractual obligations were $10.678 million, including leases and license fees.
- The filing highlights clinical, regulatory, manufacturing, competition, intellectual-property, collaboration and financing risks. Clinical evidence was limited, trial timing and costs uncertain, and the FDA had previously requested additional information for the rapid-manufacture CD19 CAR-T trial.
- Ziopharm and TriArm had incorporated Eden BioCell in Hong Kong to pursue CD19 CAR-T development in China, Taiwan and Korea. TriArm had committed up to $35 million; definitive agreements were expected in the first half of 2019, so the venture’s final terms and execution remained prospective.
- No material legal proceedings were identified by management. The filing states that disclosure controls were effective and that no material change in internal control over financial reporting occurred during the quarter.
Important facts for investors to verify
- Confirm the issuer identity and corporate-name history: this source filing is for ZIOPHARM Oncology, Inc., despite the request metadata naming Alaunos Therapeutics.
- Check subsequent cash, financing, and operating updates against the stated runway into Q2 2020; the runway estimate is forward-looking and no additional capital was committed in this filing.
- Verify actual FDA and clinical-trial milestones, particularly the CD19 CAR-T information request, planned TCR trial, and Controlled IL-12 studies; the filing’s expectations are not guarantees.
- Review dilution exposure: 18.939 million warrants from the November 2018 private placement were exercisable six months after closing at $3.01 per share, in addition to outstanding options and restricted stock.
- Assess the terms and completion of the Eden BioCell arrangements and the availability and permitted use of the $26.4 million in MD Anderson cash resources recorded as prepaid assets.